Briefing
2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
ctDNA positivity rose with stage (IB 9%, II 14%, IIIA 29%) and was associated with worse DFS. In stage II-IIIA disease, atezolizumab improved DFS versus BSC in both ctDNA-positive and ctDNA-negative patients, with clearer benefit when PD-L1 TC was >=1% (ctDNA-negative HR 0.57, 95% CI 0.36-0.90; ctDNA-positive HR 0.54, 95% CI 0.31-0.93). Among PD-L1 TC <1% patients, HRs were 0.95 (ctDNA-negative) and 0.88 (ctDNA-positive).
- Design: oral
- n: 600 ctDNA-evaluable of 1,005 randomized; 534 with stage II-IIIA disease
- Assay: Natera Signatera RUO (plasma after surgery and before adjuvant chemotherapy)